MGM-15 vs. MGM-16: What to Know About New 7-OH-Related Kratom Compounds

As federal attention grows around 7-hydroxymitragynine, also known as 7-OH, two related names are starting to appear more often: MGM-15 and MGM-16. These substances are not traditional kratom leaf. They are synthetic or semi-synthetic compounds related to 7-OH, and federal agencies have identified them as part of the same growing public health concern.

For people in Maine using kratom extracts, 7-OH tablets, gummies, liquid shots, or other opioid-like products, MGM-15 and MGM-16 may be confusing. They may sound like product codes, supplement names, or harmless research terms. In reality, they are emerging opioid-acting substances that may carry serious risks for dependence, withdrawal, and relapse.

This article explains the difference between MGM-15 and MGM-16, why they are being discussed alongside 7-OH, and when it may be time to seek professional addiction treatment.

What Are MGM-15 and MGM-16?

MGM-15 and MGM-16 are compounds related to 7-hydroxymitragynine, the potent opioid-like alkaloid associated with certain concentrated kratom products. While plain kratom leaf contains many naturally occurring alkaloids, products involving 7-OH, MGM-15, or MGM-16 are different because they may involve concentrated, modified, or synthesized substances.

In July 2026, the DEA announced its intent to temporarily schedule 7-OH and related substances to protect public safety. The announcement specifically named mitragynine pseudoindoxyl, MGM-15, and MGM-16 as related substances of concern. The Department of Health and Human Services also described 7-OH, mitragynine pseudoindoxyl, MGM-15, and MGM-16 as dangerous opioids that may fuel addiction and place people at risk.

The biggest concern is that these substances may act on opioid receptors in ways that are stronger or less predictable than traditional kratom products.

MGM-15 vs. MGM-16: Quick Comparison

What Is MGM-15?

MGM-15 is commonly described as dihydro-7-hydroxymitragynine. In simpler terms, it is a modified compound related to 7-OH. It is not the same as drinking plain kratom tea or using raw kratom leaf powder.

MGM-15 has drawn concern because it appears to interact with opioid receptors. That means it may produce effects that overlap with other opioid-like substances, including sedation, euphoria, tolerance, withdrawal, and cravings.

People may not always know they are taking MGM-15. In some cases, substances related to 7-OH may be sold in branded products, enhanced kratom products, tablets, gummies, shots, or capsules. The product label may not clearly explain what is inside, how strong it is, or whether the compound has been modified.

What Is MGM-16?

MGM-16 is another 7-OH-related compound that has been discussed as a more potent derivative. HHS described MGM-16 as the 9-fluoro derivative of 7-hydroxymitragynine. That kind of chemical modification matters because small changes to a compound can sometimes change potency, duration, receptor activity, and risk.

For the average person, the key point is simple: MGM-16 is not regular kratom. It is part of a newer category of 7-OH-related substances that may have stronger opioid-like activity and less real-world safety information.

Because MGM-16 is newer and less familiar to the public, there may be even more uncertainty around dosing, withdrawal, interactions, and overdose risk. That uncertainty is one reason federal agencies have identified it alongside 7-OH and MGM-15.

Are MGM-15 and MGM-16 the Same Thing?

No. MGM-15 and MGM-16 are related, but they are not identical.

MGM-15 is often referred to as dihydro-7-hydroxymitragynine. MGM-16 is described as a related fluorinated derivative. Both are connected to 7-OH chemistry, but chemical differences may affect how strongly they act on opioid receptors and how risky they may be.

The problem is that consumers are rarely given a clear explanation. Someone may buy a product marketed as “kratom,” “7-OH,” “extra strength,” “legal opioid alternative,” or “wellness support” without realizing that the product may contain a much stronger opioid-acting compound.

Why Are MGM-15 and MGM-16 Being Compared to 7-OH?

7-OH has become a major public health concern because it may appear in concentrated products sold as tablets, gummies, liquid shots, capsules, powders, and other retail items. The FDA has warned that 7-OH can bind to opioid receptors and that products containing concentrated or added 7-OH may pose serious risks.

MGM-15 and MGM-16 are being compared to 7-OH because they are related compounds that may produce opioid-like effects. As regulators focus more closely on 7-OH, public health officials are also watching related substances that could be used to replace it in the marketplace.

This creates a “whack-a-mole” problem. When one substance is restricted, manufacturers may shift to a related compound that is slightly different chemically but still carries similar or even greater risks.

Why This Matters for People in Maine

In Maine and across New England, kratom and 7-OH products may be sold online or in convenience stores, vape shops, smoke shops, gas stations, and wellness-style packaging. Many people do not start using these products to get high. Some begin because they are trying to manage pain, anxiety, depression, opioid withdrawal, or fatigue.

That does not make them immune to dependence.

A person may start with what seems like a legal or natural product and gradually find themselves needing it every day. Over time, they may experience withdrawal symptoms when they try to stop. With newer substances like MGM-15 and MGM-16, the risk can be even harder to judge because the consumer may not know exactly what they are taking.

Possible Risks of MGM-15 and MGM-16

Because MGM-15 and MGM-16 are emerging substances, the full human health risk profile is still developing. However, based on their relationship to 7-OH and opioid receptor activity, possible concerns include:

• Tolerance
• Dependence
• Withdrawal symptoms
• Cravings
• Sedation
• Impairment
• Risky interactions with alcohol or benzodiazepines
• Risky interactions with opioids or other depressants
• Unknown product strength
• Misleading labeling
• Increased relapse risk for people with opioid use disorder
• Difficulty stopping without support

The danger is not only the chemical itself. It is also the lack of regulation, inconsistent packaging, uncertain dosing, and the false sense of safety that can come with products sold outside traditional illicit drug markets.

Can MGM-15 or MGM-16 Cause Withdrawal?

It is possible that people using opioid-acting 7-OH-related products may experience withdrawal when they reduce or stop use. Symptoms may vary based on the product, dose, frequency, length of use, and whether other substances are involved.

Possible withdrawal symptoms may include:

• Sweating
• Chills
• Restlessness
• Anxiety
• Insomnia
• Muscle aches
• Fatigue
• Stomach cramps
• Nausea
• Diarrhea
• Irritability
• Low mood
• Cravings

Someone who has a history of opioid use disorder may be especially vulnerable. If MGM-15, MGM-16, 7-OH, or kratom extracts are being used to avoid withdrawal from opioids, stopping suddenly can increase the risk of relapse to fentanyl, heroin, prescription opioids, or other dangerous substances.

MGM-15, MGM-16, and Opioid Relapse Risk

One of the most important treatment concerns is that people may use these substances as a bridge away from illicit opioids. At first, that can feel like harm reduction. The person may believe they are choosing something legal, safer, or more manageable.

But when a substance has opioid-like effects, the body can still adapt to it. A person may still experience cravings, withdrawal, and compulsive use. If the product becomes unavailable or too expensive, the person may feel pushed back toward illicit opioids.

This is why professional support matters. Treatment can help a person stabilize without relying on unknown products, inconsistent packaging, or substances that may become legally restricted.

Treatment for 7-OH, MGM-15, MGM-16, and Kratom Extract Use

Treatment should be based on the person’s symptoms, substance use history, medical needs, mental health, and relapse risk. There is no one-size-fits-all approach.

Helpful options may include:

• Medical assessment
• Detox when clinically appropriate
• Medication-Assisted Treatment when appropriate
• Outpatient treatment
• Individual therapy
• Group therapy
• Relapse prevention planning
• Mental health support
• Family education
• Aftercare planning

Medication-assisted treatment, or MAT, can be especially helpful for people who are using 7-OH-related products to avoid opioid withdrawal or cravings. MAT provides a supervised, clinically monitored alternative instead of relying on unknown product contents or moving to illicit drugs when access changes.

How Portland Treatment Can Help

Portland Treatment helps people in Maine who are struggling with substance use, withdrawal concerns, cravings, and relapse risk. If you have been using 7-OH, MGM-15, MGM-16, kratom extracts, opioids, or multiple substances, you do not have to figure it out alone.

Many people feel ashamed because they thought they were using something legal, natural, or safer than opioids. But dependence can happen even when the original intention was to avoid worse outcomes.

Our team can help you understand your options, determine what level of care may be appropriate, and create a safer plan for recovery.

Frequently Asked Questions About MGM-15 and MGM-16

Is MGM-15 the same as kratom?

No. MGM-15 is related to kratom alkaloid chemistry, but it is not the same as natural kratom leaf. It is generally discussed as a synthetic or semi-synthetic compound related to 7-OH.

Is MGM-16 the same as 7-OH?

No. MGM-16 is related to 7-OH, but it is a different compound. HHS has described MGM-16 as a 9-fluoro derivative of 7-hydroxymitragynine.

Are MGM-15 and MGM-16 opioids?

Federal health officials have described 7-OH, mitragynine pseudoindoxyl, MGM-15, and MGM-16 as dangerous opioids. These substances are concerning because of their opioid receptor activity and potential for dependence, withdrawal, and misuse.

Are MGM-15 and MGM-16 federally scheduled?

In July 2026, the DEA announced its intent to temporarily schedule 7-OH and related substances, including MGM-15 and MGM-16. If temporary scheduling orders take effect, covered substances would be subject to federal Schedule I controls.

Can MGM-15 or MGM-16 show up in kratom products?

Consumers may not always know what is in a product. Some products marketed as kratom, enhanced kratom, 7-OH, or opioid alternatives may contain concentrated or modified compounds. This is why product labeling and unregulated retail sales are such a concern.

Should I stop using MGM-15, MGM-16, or 7-OH cold turkey?

It is safest to speak with a medical or addiction treatment professional before stopping, especially if you use these products daily, use high doses, combine them with other substances, or have a history of opioid use disorder. Withdrawal and cravings can increase relapse risk.

Sources

Drug Enforcement Administration. (2026, July 1). DEA to temporarily schedule 7-OH and related substances to protect public safety. https://www.dea.gov/press-releases/2026/07/01/dea-temporarily-schedule-7-oh-and-related-substances-protect-public

Food and Drug Administration. (2025, July 29). FDA takes steps to restrict 7-OH opioid products threatening American consumers. https://www.fda.gov/news-events/press-announcements/fda-takes-steps-restrict-7-oh-opioid-products-threatening-american-consumers

Food and Drug Administration. (2025, July 29). Products containing 7-OH can cause serious harm. https://www.fda.gov/consumers/consumer-updates/products-containing-7-oh-can-cause-serious-harm

Reuters. (2026, July 1). DEA moves to place some strong kratom-related products under strict federal drug controls. https://www.reuters.com/legal/litigation/dea-moves-place-some-strong-kratom-related-products-under-strict-federal-drug-2026-07-01/

U.S. Department of Health and Human Services. (2026, July 1). HHS, FDA commend DEA action against dangerous enhanced 7-OH products. https://www.hhs.gov/press-room/hhs-fda-support-dea-7-oh-scheduling.html

WIRED. (2026, July 2). The DEA plans to ban opioid-like kratom compound 7-OH. https://www.wired.com/story/the-dea-plans-to-ban-kratom-compound-7-oh-sold-as-a-gas-station-opioid/